Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NSP012
MIFTS: 65

Nasopharyngeal Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Nasopharyngeal Carcinoma

About this section

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 58 12 77 54 60 30 13 56 6 15 41 74
Nasopharyngeal Cancer 58 54 38
Malignant Neoplasm of Nasopharynx 12 74
Nasopharyngeal Neoplasms 45 74
Nasopharynx Carcinoma 12 15
Npc 58 17
Malignant Neoplasm of Other Specified Sites of Nasopharynx 12
Primary Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Posterior Wall of Nasopharynx 12
Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Superior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx 12
Malignant Tumor of Posterior Wall of Nasopharynx 12
Malignant Tumor of Anterior Wall of Nasopharynx 12
Malignant Tumor of Lateral Wall of Nasopharynx 12
Squamous Cell Carcinoma of the Nasopharynx 60
Malignant Neoplasm of Nasopharyngeal Wall 12
Malignant Neoplasm of Roof of Nasopharynx 12
Malignant Nasopharyngeal Tumor 12
Nasopharyngeal Carcinoma 1 58
Carcinoma of Nasopharynx 12
Nasopharyngeal Neoplasm 17
Cancer of Nasopharynx 74
Nasopharynx Cancer 12
Npca 58

Characteristics:

Orphanet epidemiological data:

60
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

33
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Respiratory diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:9261
OMIM 58 607107
KEGG 38 H00054
MeSH 45 D009303
NCIt 51 C9321
MESH via Orphanet 46 C538339
ICD10 via Orphanet 35 C11.0 C11.1 C11.2 more
UMLS via Orphanet 75 C0153392 C0238301 C2931822
Orphanet 60 ORPHA150
MedGen 43 C2931822
SNOMED-CT via HPO 70 126680004
Sources

Summaries for Nasopharyngeal Carcinoma

About this section
OMIM : 58 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107)

MalaCards based summary : Nasopharyngeal Carcinoma, also known as nasopharyngeal cancer, is related to squamous cell carcinoma and leukemia, and has symptoms including headache, tinnitus and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Cisplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, bone and t cells, and related phenotype is neoplasia of the nasopharynx.

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or \

Wikipedia : 77 Nasopharynx cancer or nasopharyngeal carcinoma (NPC) is the most common cancer originating in the... more...

Sources

Related Diseases for Nasopharyngeal Carcinoma

About this section

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 366)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.0 CDKN2B-AS1 FOXCUT H19 HOTAIR HRAS MALAT1
2 leukemia 31.0 CDKN2B-AS1 HOTAIR NEAT1 NRAS TP53
3 adenocarcinoma 30.8 H19 HRAS MALAT1 PIK3CA TP53
4 osteogenic sarcoma 30.5 CDKN2B-AS1 H19 HOTAIR MALAT1 NEAT1 TP53
5 acute lymphocytic leukemia 30.5 CDKN2B-AS1 TP53 XIST
6 tongue squamous cell carcinoma 30.5 AFAP1-AS1 MALAT1 TP53
7 squamous cell carcinoma, head and neck 30.5 H19 HOTAIR HRAS MIR29C PIK3CA TP53
8 laryngeal squamous cell carcinoma 30.4 CDKN2B-AS1 H19 HOTAIR MALAT1 NEAT1 TP53
9 myeloma, multiple 30.3 H19 HOTAIR HRAS MALAT1 NRAS TP53
10 renal cell carcinoma, nonpapillary 30.3 H19 HOTAIR MALAT1 NPTN-IT1
11 esophageal cancer 30.2 CDKN2B-AS1 FOXD2-AS1 H19 HOTAIR HRAS MALAT1
12 thyroid cancer 30.1 AFAP1-AS1 CDKN2B-AS1 H19 HOTAIR HRAS LINC00312
13 prostate cancer 30.1 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1 MIR100
14 breast cancer 30.1 CDKN2B-AS1 FOXCUT H19 HOTAIR HRAS MALAT1
15 melanoma 30.0 CDKN2B-AS1 H19 HOTAIR MALAT1 MIR100 NRAS
16 hepatocellular carcinoma 29.9 AFAP1-AS1 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1
17 lung cancer 29.7 AFAP1-AS1 CDKN2B-AS1 FOXD2-AS1 H19 HOTAIR HRAS
18 nasopharyngeal carcinoma 3 12.7
19 nasopharyngeal carcinoma 2 12.5
20 nasopharyngeal cancer, childhood 12.2
21 niemann-pick disease, type c1 12.1
22 lymphoepithelioma-like carcinoma 11.6
23 niemann-pick disease, type c2 11.1
24 serous cystadenocarcinoma 10.7 HRAS PIK3CA TP53
25 cystadenocarcinoma 10.7 HRAS PIK3CA TP53
26 ovary adenocarcinoma 10.7 HRAS PIK3CA TP53
27 adult hepatocellular carcinoma 10.7 PIK3CA TP53
28 skin squamous cell carcinoma 10.7 HRAS PIK3CA TP53
29 malignant ovarian surface epithelial-stromal neoplasm 10.7 HRAS PIK3CA TP53
30 ovary epithelial cancer 10.7 HRAS PIK3CA TP53
31 rare adenocarcinoma of the breast 10.7 PIK3CA TP53
32 respiratory system cancer 10.7 HRAS MALAT1 PIK3CA TP53
33 carcinosarcoma 10.7 HRAS PIK3CA TP53
34 malignant spiradenoma 10.6 PIK3CA TP53
35 apocrine adenoma 10.6 HRAS PIK3CA
36 uterine carcinosarcoma 10.6 HRAS PIK3CA TP53
37 prostate adenoid cystic carcinoma 10.6 HRAS PIK3CA
38 intestinal disease 10.6 HRAS PIK3CA TP53
39 small cell cancer of the lung 10.6 HOTAIR MALAT1 PIK3CA TP53
40 triple-receptor negative breast cancer 10.6 HOTAIR MALAT1
41 prostate disease 10.6 CDKN2B-AS1 H19 MALAT1 TP53
42 esophagus squamous cell carcinoma 10.6 AFAP1-AS1 HOTAIR
43 suppression of tumorigenicity 12 10.6 HRAS PIK3CA TP53
44 ovarian epithelial cancer 10.6 H19 HOTAIR MALAT1 PIK3CA
45 spitz nevus 10.6 HRAS TP53
46 lung squamous cell carcinoma 10.6 HRAS NPTN-IT1 PIK3CA TP53
47 kidney cancer 10.6 H19 HOTAIR MALAT1 MIR29C TP53
48 gastrointestinal system cancer 10.6 H19 HOTAIR HRAS MALAT1 PIK3CA TP53
49 meningeal melanomatosis 10.6 HRAS NRAS TP53
50 hematologic cancer 10.6 HRAS NFKBIA TP53 XIST

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma
Sources

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

About this section

Human phenotypes related to Nasopharyngeal Carcinoma:

33
# Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 33 HP:0100630

Clinical features from OMIM:

607107

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache, tinnitus, rhinorrhea
Sources

Drugs & Therapeutics for Nasopharyngeal Carcinoma

About this section

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
3
Bupropion Approved Phase 4,Phase 2,Early Phase 1 34841-39-9, 34911-55-2 444
4
Dopamine Approved Phase 4,Phase 2,Early Phase 1 62-31-7, 51-61-6 681
5
Nicotine Approved Phase 4,Early Phase 1,Not Applicable 54-11-5 89594 942
6
Nimotuzumab Investigational Phase 4,Phase 3,Phase 2,Phase 1 780758-10-3, 828933-61-3
7 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
11 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
15 Dopamine Uptake Inhibitors Phase 4,Phase 2,Early Phase 1
16 Antidepressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Early Phase 1
18 Dopamine Agents Phase 4,Phase 2,Early Phase 1
19 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Early Phase 1
20 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Early Phase 1
21 Central Nervous System Stimulants Phase 4,Phase 3,Early Phase 1,Not Applicable
22 Nicotinic Agonists Phase 4,Early Phase 1,Not Applicable
23 Cholinergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
24
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
25
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
26
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
27
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
Palonosetron Approved, Investigational Phase 3,Phase 2 135729-61-2, 135729-56-5, 119904-90-4 148211
30
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
31
Aprepitant Approved, Investigational Phase 3,Phase 2 170729-80-3 6918365 151165
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
33
Fosaprepitant Approved Phase 3,Phase 2 172673-20-0 219090
34
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
35
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
36
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
37
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
38
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
39
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
40
Cetuximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
41
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
42
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
43
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
44
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
45
Sargramostim Approved, Investigational Phase 3,Phase 2,Not Applicable 123774-72-1, 83869-56-1
46
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
47
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
48
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
49
Acyclovir Approved Phase 3 59277-89-3 2022
50
Oprelvekin Approved, Investigational Phase 3 145941-26-0

Interventional clinical trials:

(show top 50) (show all 615)
# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
2 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury Unknown status NCT03069820 Phase 4 docetaxel and cisplatin
3 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
4 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
6 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
7 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
8 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
9 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Unknown status NCT01817023 Phase 3 Cisplatin
10 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
11 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
12 Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
13 Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
14 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
15 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
16 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
17 EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients Unknown status NCT03006588 Phase 2, Phase 3
18 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
19 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
20 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
21 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
22 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. Unknown status NCT00180973 Phase 3 Hydroxyurea
23 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
24 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
25 Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Unknown status NCT02933099 Phase 3 Aprepitant+palonosetron+dexamethasone;palonosetron+dexamethasone
26 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
27 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
28 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
29 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
30 Phase â…¢ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma Recruiting NCT03321539 Phase 3 CCRT+GP;CCRT+PF
31 TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma Recruiting NCT03306121 Phase 3 TPF+CCRT;CCRT+ PF
32 TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma Recruiting NCT02940925 Phase 3
33 IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma Not yet recruiting NCT03068936 Phase 3 Cisplatin
34 The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT Active, not recruiting NCT02460887 Phase 3 Gemcitabine;cisplatin;cisplatin
35 Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Not yet recruiting NCT02907710 Phase 3 Endostar;DDP
36 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
37 Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT02958111 Phase 3 Capecitabine
38 Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02460419 Phase 3 capecitabine
39 Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma Recruiting NCT03707509 Phase 3 Camrelizumab;Placebos;Gemcitabine;Cisplatin
40 Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma Recruiting NCT02111460 Phase 3
41 Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma Recruiting NCT03015727 Phase 3 Docetaxel;Cisplatin;Chemotherapy
42 Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma Not yet recruiting NCT02786641 Phase 3 Docetaxel;Cisplatin 1;Xeloda;Cisplatin 2
43 Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT01872962 Phase 3 gemcitabine and cisplatin (Induction chemotherapy)
44 A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients Recruiting NCT02578641 Phase 3 combination IV gemcitabine and IV carboplatin (AUC2)
45 Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage Recruiting NCT03403829 Phase 3 Gemcitabine
46 Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma Recruiting NCT03601975 Phase 3 Gemcitabine/Cisplatin
47 A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma Recruiting NCT02512315 Phase 3 Docetaxel (DOC);Cisplatin (DDP)
48 Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial Active, not recruiting NCT02143388 Phase 2, Phase 3 IMRT combine with cisplatin concurrent chemotherapy;IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
49 Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma Not yet recruiting NCT03344068 Phase 2, Phase 3 Chemotherapy
50 Programmed Death-1 (PD-1) Antibody Combined With IMRT in Recurrent Nasopharyngeal Carcinoma Patients Not yet recruiting NCT03907826 Phase 3 PD-1 blocking antibody

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Sources

Genetic Tests for Nasopharyngeal Carcinoma

About this section

Genetic tests related to Nasopharyngeal Carcinoma:

# Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 30 TP53
Sources

Anatomical Context for Nasopharyngeal Carcinoma

About this section

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

42
Lymph Node, Bone, T Cells, Brain, Liver, Skin, Prostate
Sources

Publications for Nasopharyngeal Carcinoma

About this section

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 5405)
# Title Authors Year
1
Carotid stenosis prevalence after radiotherapy in nasopharyngeal carcinoma: A meta-analysis. ( 30935575 )
2019
2
A nomogram for the prediction of cerebrovascular disease among patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma. ( 30825967 )
2019
3
EBV-Associated Non-keratinizing Nasopharyngeal Carcinoma with Prominent Spindled Cell and Whorling Patterns: A Previously Unreported Histological Variant in a Patient Presenting with Dermatomyositis. ( 30758756 )
2019
4
Office-Based Cricopharyngeus Balloon Dilation for Post Chemoirradiation Dysphagia in Nasopharyngeal Carcinoma Patients: A Pilot Study. ( 30888528 )
2019
5
Radiotherapy-induced dysphagia and its impact on quality of life in patients with nasopharyngeal carcinoma. ( 30689027 )
2019
6
miR-193a-3p Promotes Radio-Resistance of Nasopharyngeal Cancer Cells by Targeting SRSF2 Gene and Hypoxia Signaling Pathway. ( 30773530 )
2019
7
Case of extranodal natural killer/T-cell lymphoma, nasal type, accompanied by Epstein-Barr virus-positive nasopharyngeal carcinoma. ( 30379350 )
2019
8
A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. ( 30521105 )
2019
9
Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial. ( 30712098 )
2019
10
Deciphering the Pharmacological Mechanism of the Herb Radix Ophiopogonis in the Treatment of Nasopharyngeal Carcinoma by Integrating iTRAQ-Coupled 2-D LC-MS/MS Analysis and Network Investigation. ( 30936832 )
2019
11
VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma. ( 30944308 )
2019
12
PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation. ( 30945396 )
2019
13
Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma. ( 30949405 )
2019
14
Prognostic implications of a molecular classifier derived from whole-exome sequencing in nasopharyngeal carcinoma. ( 30950204 )
2019
15
The development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensity-modulated radiotherapy era. ( 30950240 )
2019
16
Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study. ( 30954521 )
2019
17
The impact of the interval between the induction of chemotherapy and radiotherapy on the survival of patients with nasopharyngeal carcinoma. ( 30962719 )
2019
18
Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience. ( 30963203 )
2019
19
Post-radiation sinusitis is associated with recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. ( 30971260 )
2019
20
Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression. ( 30972891 )
2019
21
MiR-1178-3p promotes the proliferation, migration and invasion of nasopharyngeal carcinoma Sune-1 cells by targeting STK4. ( 30972994 )
2019
22
High SRC-1 and Twist1 expression predicts poor prognosis and promotes migration and invasion by inducing epithelial-mesenchymal transition in human nasopharyngeal carcinoma. ( 30973923 )
2019
23
Reducing NETO2 expression prevents human nasopharyngeal carcinoma (NPC) progression by suppressing metastasis and inducing apoptosis. ( 30975469 )
2019
24
Prognostic Value of Deep Learning PET/CT-based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma. ( 30975664 )
2019
25
PPARβ/δ Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by regulating miR206. ( 30982495 )
2019
26
PD-L1 induces epithelial mesenchymal transition in nasopharyngeal carcinoma cells through activation PI3K/AKT pathway. ( 30982497 )
2019
27
Licochalcone A induces apoptotic cell death via JNK/p38 activation in human nasopharyngeal carcinoma cells. ( 30983163 )
2019
28
Adjunctive Chinese herbal medicine therapy for nasopharyngeal carcinoma: Clinical evidence and experimental validation. ( 30985039 )
2019
29
Target delineation and dose prescription of adaptive replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma. ( 30987678 )
2019
30
Identification of key pathways and genes in nasopharyngeal carcinoma using bioinformatics analysis. ( 30988824 )
2019
31
Prevalence and Associated Impacts of Cervical Esophageal Clearance Issues Post Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC). ( 30989394 )
2019
32
Starvation-induced autophagy is up-regulated via ROS-mediated ClC-3 chloride channel activation in the nasopharyngeal carcinoma cell line CNE-2Z. ( 30992317 )
2019
33
A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma. ( 30993588 )
2019
34
Long noncoding RNA PTPRG-AS1 acts as a microRNA-194-3p sponge to regulate radiosensitivity and metastasis of nasopharyngeal carcinoma cells via PRC1. ( 30993702 )
2019
35
Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation. ( 31000196 )
2019
36
Nasopharyngeal carcinoma with cutaneous metastases. ( 31000368 )
2019
37
miR-143 inhibits proliferation and metastasis of nasopharyngeal carcinoma cells via targeting FMNL1 based on clinical and radiologic findings. ( 31001854 )
2019
38
CircRNA ZNF609 promotes growth and metastasis of nasopharyngeal carcinoma by competing with microRNA-150-5p. ( 31002133 )
2019
39
Isoliquiritigenin suppresses the proliferation and induced apoptosis via miR-32/LATS2/Wnt in nasopharyngeal carcinoma. ( 31004603 )
2019
40
Subclassification of skull-base invasion for nasopharyngeal carcinoma using cluster, network and survival analyses: A double-center retrospective investigation. ( 31005222 )
2019
41
Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy. ( 31006996 )
2019
42
Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients. ( 31010621 )
2019
43
Epigallocatechin-3-gallate inhibits migration of human nasopharyngeal carcinoma cells by repressing MMP-2 expression. ( 31012106 )
2019
44
Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma. ( 31014565 )
2019
45
Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma? ( 31019954 )
2019
46
FOXO3a knockdown promotes radioresistance in nasopharyngeal carcinoma by inducing epithelial-mesenchymal transition and the Wnt/β-catenin signaling pathway. ( 31022422 )
2019
47
Sodium butyrate induces autophagic apoptosis of nasopharyngeal carcinoma cells by inhibiting AKT/mTOR signaling. ( 31023529 )
2019
48
A Nomogram for the Prediction of Prognosis in Patients With Distant Metastases of Nasopharyngeal Carcinoma. ( 31024844 )
2019
49
Milk Consumption Across Life Periods in Relation to Lower Risk of Nasopharyngeal Carcinoma: A Multicentre Case-Control Study. ( 31024854 )
2019
50
Wnt/β-Catenin Signaling Pathway-Related Proteins (DKK-3, β-Catenin, and c-MYC) Are Involved in Prognosis of Nasopharyngeal Carcinoma. ( 31025872 )
2019
Sources

Variations for Nasopharyngeal Carcinoma

About this section

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6 (show top 50) (show all 76)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
3 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
4 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
5 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
6 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
7 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic rs28934578 GRCh37 Chromosome 17, 7578406: 7578406
8 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic rs28934578 GRCh38 Chromosome 17, 7675088: 7675088
9 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
10 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
11 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
12 HRAS NM_005343.2(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
13 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 HRAS NM_005343.2(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
15 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
17 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
18 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
20 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
22 NRAS NM_002524.3(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
23 NRAS NM_002524.3(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
24 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
25 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh38 Chromosome 1, 114713909: 114713909
26 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 NCBI36 Chromosome 1, 115058053: 115058053
27 TP53 NM_000546.5(TP53): c.466C> T (p.Arg156Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs563378859 GRCh37 Chromosome 17, 7578464: 7578464
28 TP53 NM_000546.5(TP53): c.466C> T (p.Arg156Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs563378859 GRCh38 Chromosome 17, 7675146: 7675146
29 TP53 NM_000546.5(TP53): c.847C> T (p.Arg283Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs149633775 GRCh37 Chromosome 17, 7577091: 7577091
30 TP53 NM_000546.5(TP53): c.847C> T (p.Arg283Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs149633775 GRCh38 Chromosome 17, 7673773: 7673773
31 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
32 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
33 TP53 NM_000546.5(TP53): c.799C> T (p.Arg267Trp) single nucleotide variant Likely pathogenic rs55832599 GRCh37 Chromosome 17, 7577139: 7577139
34 TP53 NM_000546.5(TP53): c.799C> T (p.Arg267Trp) single nucleotide variant Likely pathogenic rs55832599 GRCh38 Chromosome 17, 7673821: 7673821
35 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
36 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
37 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
38 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
39 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
40 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
41 TP53 NM_000546.5(TP53): c.461G> A (p.Gly154Asp) single nucleotide variant Uncertain significance rs762846821 GRCh37 Chromosome 17, 7578469: 7578469
42 TP53 NM_000546.5(TP53): c.461G> A (p.Gly154Asp) single nucleotide variant Uncertain significance rs762846821 GRCh38 Chromosome 17, 7675151: 7675151
43 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
44 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
45 NRAS NM_002524.3(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
46 NRAS NM_002524.3(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
47 NRAS NM_002524.3(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
48 NRAS NM_002524.3(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907
49 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh37 Chromosome 10, 123258036: 123258036
50 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh38 Chromosome 10, 121498522: 121498522

Cosmic variations for Nasopharyngeal Carcinoma:

9 (show top 50) (show all 818)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM2255920 ZNF609 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1984G>A p.A662T 15:64674838-64674838 0
2 COSM6948029 ZFHX3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.8780G>T p.S2927I 16:72793902-72793902 0
3 COSM6973489 ZFHX3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.9572G>A p.G3191D 16:72788704-72788704 0
4 COSM4995216 ZC3H13 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.44C>G p.T15S 13:46045464-46045464 0
5 COSM4995307 ZBTB17 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.281C>T p.A94V 1:15947048-15947048 0
6 COSM6924419 YAP1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1178C>A p.A393D 11:102229765-102229765 0
7 COSM4995092 VPS33A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.221C>A p.A74D 12:122263647-122263647 0
8 COSM4996600 VNN2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.83C>A p.A28D 6:132757801-132757801 0
9 COSM4995249 VANGL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.884T>C p.L295P 1:115682435-115682435 0
10 COSM4996245 USP34 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5131C>T p.Q1711* 2:61281110-61281110 0
11 COSM4997193 USP19 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3636G>T p.L1212F 3:49110728-49110728 0
12 COSM4995369 USH2A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.89T>C p.L30S 1:216422248-216422248 0
13 COSM2978223 USH1G upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.520G>A p.D174N 17:74920316-74920316 0
14 COSM4995852 USE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.370G>T p.E124* 19:17216307-17216307 0
15 COSM4996719 TTBK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1757G>A p.R586Q 6:43263121-43263121 0
16 COSM4997149 TSR2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.187G>C p.D63H 23:54443414-54443414 0
17 COSM1524842 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1783G>A p.D595N 19:31277461-31277461 0
18 COSM4995873 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1121C>T p.P374L 19:31278123-31278123 0
19 COSM6956334 TSC2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1753C>T p.R585C 16:2070492-2070492 0
20 COSM6908589 TSC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.973C>T p.Q325* 9:132911509-132911509 0
21 COSM6973473 TSC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2190G>T p.E730D 9:132903669-132903669 0
22 COSM4995721 TRAF4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.955C>G p.R319G 17:28749119-28749119 0
23 COSM6973476 TRAF2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.4G>A p.A2T 9:136898744-136898744 0
24 COSM6807199 TRAF2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1177C>T p.R393C 9:136923890-136923890 0
25 COSM2123037 TPR upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3879G>A p.M1293I 1:186341261-186341261 0
26 COSM4996315 TP63 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1413C>G p.S471R 3:189886457-189886457 0
27 COSM10662 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
28 COSM10660 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.818G>A p.R273H 17:7673802-7673802 0
29 COSM10808 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.488A>G p.Y163C 17:7675124-7675124 0
30 COSM43650 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.638G>T p.R213L 17:7674893-7674893 0
31 COSM11376 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.737T>G p.M246R 17:7674226-7674226 0
32 COSM43708 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.422G>A p.C141Y 17:7675190-7675190 0
33 COSM45026 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.560-2A>T p.? 17:7674973-7674973 0
34 COSM43555 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.736A>G p.M246V 17:7674227-7674227 0
35 COSM10654 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.637C>T p.R213* 17:7674894-7674894 0
36 COSM10648 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.524G>A p.R175H 17:7675088-7675088 0
37 COSM10659 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
38 COSM11073 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1024C>T p.R342* 17:7670685-7670685 0
39 COSM10656 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 0
40 COSM10645 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.527G>T p.C176F 17:7675085-7675085 0
41 COSM45589 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1037A>C p.E346A 17:7670672-7670672 0
42 COSM69404 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.994-1G>A p.? 17:7670716-7670716 0
43 COSM10943 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.841G>C p.D281H 17:7673779-7673779 0
44 COSM10724 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.839G>C p.R280T 17:7673781-7673781 0
45 COSM45243 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.374C>G p.T125R 17:7675995-7675995 0
46 COSM11181 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.764T>C p.I255T 17:7674199-7674199 0
47 COSM43906 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.843C>A p.D281E 17:7673777-7673777 0
48 COSM43919 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.856G>T p.E286* 17:7673764-7673764 0
49 COSM10790 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.455C>T p.P152L 17:7675157-7675157 0
50 COSM11354 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.991C>T p.Q331* 17:7673537-7673537 0

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270-1 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270-2 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification EVI1 Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MDS1 Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion LMP1 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion LMP2 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication LOC100132832 Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2L11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer
Sources

Expression for Nasopharyngeal Carcinoma

About this section
Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.
Sources

Pathways for Nasopharyngeal Carcinoma

About this section

Pathways related to Nasopharyngeal Carcinoma according to KEGG:

38
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 38
Show member pathways
 12.83 HRAS NFKBIA NRAS PIK3CA TP53
2
Pathways in cancer 38
12.79 HRAS NFKBIA NRAS PIK3CA TP53
3
Apoptosis Modulation and Signaling 1
Show member pathways
 12.74 HRAS NFKBIA NRAS PIK3CA TP53
4
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.64 HRAS NFKBIA NRAS PIK3CA TP53
5
Development HGF signaling pathway 23
Show member pathways
 12.61 HRAS NFKBIA NRAS PIK3CA TP53
6
ErbB signaling pathway 1 38
Show member pathways
 12.55 HRAS NRAS PIK3CA TP53
7
T cell receptor signaling pathway 38
Show member pathways
 12.5 HRAS NFKBIA NRAS PIK3CA
8
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.47 HRAS NRAS PIK3CA TP53
9
Prolactin Signaling Pathway 1 38
Show member pathways
 12.45 HRAS NFKBIA NRAS PIK3CA
10
Immune response IL-23 signaling pathway 23
Show member pathways
 12.43 HRAS NFKBIA NRAS PIK3CA TP53
11
Development FGFR signaling pathway 23
Show member pathways
 12.41 HRAS NFKBIA NRAS PIK3CA
12
VEGF Pathway (Qiagen) 65
Show member pathways
 12.38 HRAS NFKBIA NRAS PIK3CA
13
Development EGFR signaling pathway 23
Show member pathways
 12.36 HRAS NFKBIA NRAS PIK3CA TP53
14
Development IGF-1 receptor signaling 23
Show member pathways
 12.33 HRAS NFKBIA PIK3CA TP53
15
B cell receptor signaling pathway (KEGG) 38
Show member pathways
 12.31 HRAS NFKBIA NRAS PIK3CA
16
Toll Comparative Pathway 65
Show member pathways
 12.25 HRAS NFKBIA PIK3CA TP53
17
B Cell Receptor Signaling Pathway (sino) 68
Show member pathways
 12.24 HRAS NFKBIA NRAS PIK3CA
18
Proteoglycans in cancer 38
12.2 HRAS NRAS PIK3CA TP53
19
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.18 HRAS NFKBIA NRAS TP53
20
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.15 HRAS NRAS PIK3CA TP53
21
Apoptosis Pathway 73
Show member pathways
 12.14 HRAS NFKBIA NRAS PIK3CA TP53
22
C-type lectin receptor signaling pathway 38
Show member pathways
 12.11 HRAS NFKBIA NRAS PIK3CA
23
GDNF-Family Ligands and Receptor Interactions 65
Show member pathways
 12.08 HRAS NFKBIA NRAS PIK3CA
24
Cellular senescence (KEGG) 38
12.05 HRAS NRAS PIK3CA TP53
25
mTOR Pathway 73
Show member pathways
 12.04 HRAS NRAS PIK3CA TP53
26
AKT Signaling Pathway 68
12.03 HRAS NRAS PIK3CA TP53
27
Development EGFR signaling via small GTPases 23
Show member pathways
 12 HRAS NFKBIA NRAS PIK3CA
28
Human T-cell leukemia virus 1 infection 38
12 HRAS NFKBIA NRAS PIK3CA TP53
29
Longevity regulating pathway 38
Show member pathways
 11.99 HRAS NRAS PIK3CA TP53
30
Glioblastoma Multiforme 65
11.93 HRAS NRAS TP53
31
Signaling by ERBB4 67
Show member pathways
 11.91 HRAS NRAS PIK3CA
32
AGE-RAGE signaling pathway in diabetic complications 38
11.88 HRAS NRAS PIK3CA
33
Viral carcinogenesis 38
11.86 HRAS NFKBIA NRAS PIK3CA TP53
34
Small cell lung cancer 38
11.83 NFKBIA PIK3CA TP53
35
Sphingolipid signaling pathway 38
11.83 HRAS NRAS PIK3CA TP53
36
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants 67
Show member pathways
 11.82 HRAS NRAS PIK3CA
37
FGFR1 mutant receptor activation 67
Show member pathways
 11.8 HRAS NRAS PIK3CA
38
Thyroid hormone signaling pathway 38
11.8 HRAS NRAS PIK3CA TP53
39
DNA Damage Response (only ATM dependent) 1
11.77 HRAS NRAS PIK3CA TP53
40
VEGF Pathway (Tocris) 62
Show member pathways
 11.73 HRAS NRAS PIK3CA
41
Bladder cancer 1 38
11.67 HRAS NRAS TP53
42
Pathways Affected in Adenoid Cystic Carcinoma 1
11.61 HRAS PIK3CA TP53
43
Mitophagy - animal 38
11.59 HRAS NRAS TP53
44
MicroRNAs in cancer 38
11.58 HRAS MIR100 MIR29C NRAS PIK3CA TP53
45
Transcription_Transcription factor Tubby signaling pathways 23
11.27 HRAS NRAS TP53
46
Telomere Extension by Telomerase 65
Show member pathways
 11.15 HRAS NFKBIA PIK3CA
47
Central carbon metabolism in cancer 38
11.07 HRAS NRAS PIK3CA TP53
48
PI3K-AKT-mTOR signaling pathway and therapeutic opportunities 1
11.02 HRAS NRAS PIK3CA
49
Nongenotropic Androgen signaling 1
10.97 HRAS PIK3CA
50
Atypical NF-kappaB pathway 1
10.84 NFKBIA PIK3CA
Sources

GO Terms for Nasopharyngeal Carcinoma

About this section

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 8.8 HRAS NRAS TP53
Sources

Sources for Nasopharyngeal Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....